2023-05-02 07:02:02 ET
- Incyte press release ( NASDAQ: INCY ): Q1 Non-GAAP EPS of $0.37 misses by $0.37 .
- Revenue of $808.67M (+10.3% Y/Y) misses by $49.92M .
- "Our first quarter results demonstrate continued year-over-year double-digit revenue growth driven by Jakafi, which grew across all indications, and Opzelura, which is on track to become one of the most successful dermatology launches in recent years. In addition, we further expanded our commercial portfolio with several regulatory approvals including Opzelura for vitiligo in Europe.” said Hervé Hoppenot, Chief Executive Officer, Incyte. "Furthermore, in Q1 we made a decision to focus our development efforts on eight programs that have high potential value for us and discontinued six other programs. This allows us to optimize our allocation of resources on programs that can have a high impact for patients and for Incyte."
For further details see:
Incyte Non-GAAP EPS of $0.37 misses by $0.37, revenue of $808.67M misses by $49.92M